NEW YORK – Scores of industry senior executives and the professionals who finance and invest in their drug development pursuits have descended upon New York – which is still in the throes of a most frigid winter – to attend the 13th annual Biotechnology International Organization (BIO) CEO & Investor Conference taking place Monday and Tuesday at the Waldorf-Astoria Hotel. They have come to address the cold-reality financial and investment landscape issues affecting continued post-recession growth in the biotechnology market.